Payment overview · 2025
General Payments
$450.33
24 reported records · 9 companies
Healthcare provider profile · identity verified
Gary Helfin, MD
Allopathic & Osteopathic Physicians|Family Medicine · DUNNELLON, FL · NPI 1093739609
Verified facts
What the public records show
CMS Open Payments records show Gary Helfin, MD received $450.33 in general payments during 2025 across 24 reported records.
Novo Nordisk Inc accounted for 38.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $174.49 | 38.8% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $68.68 | 15.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.77 | 9.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.00 | 8.9% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $30.65 | 6.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.18 | 6.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $25.99 | 5.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.66 | 4.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.91 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $450.33 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $159.74 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $104.61 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $68.68 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $68.68 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $43.77 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.77 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.18 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $25.99 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $25.99 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 71 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
47 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 434 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 395 | 118 |
| Atorvastatin Calcium | Atorvastatin Calcium | 376 | 104 |
| Lisinopril | Lisinopril | 287 | 79 |
| Omeprazole | Omeprazole | 257 | 79 |
| Losartan Potassium | Losartan Potassium | 252 | 70 |
| Alprazolam | Alprazolam | 249 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 246 | 67 |
| Tramadol Hcl | Tramadol Hcl | 235 | 49 |
| Gabapentin | Gabapentin | 220 | 58 |
| Simvastatin | Simvastatin | 200 | 54 |
| Metformin Hcl | Metformin Hcl | 192 | 52 |
| Methylprednisolone | Methylprednisolone | 184 | 138 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 51 |
| Azithromycin | Azithromycin | 152 | 123 |
| Amoxicillin | Amoxicillin | 139 | 87 |
| Montelukast Sodium | Montelukast Sodium | 138 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 135 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 129 | 24 |
| Sertraline Hcl | Sertraline Hcl | 127 | 36 |
| Prednisone | Prednisone | 123 | 46 |
| Atenolol | Atenolol | 119 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 111 | 30 |
| Furosemide | Furosemide | 107 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 28 |
| Lorazepam | Lorazepam | 100 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 89 | 66 |
| Carvedilol | Carvedilol | 88 | 28 |
| Irbesartan | Irbesartan | 86 | 21 |
| Synthroid | Levothyroxine Sodium | 85 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 18 |
| Meloxicam | Meloxicam | 80 | 28 |
| Ozempic | Semaglutide | 76 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 18 |
| Propranolol Hcl | Propranolol Hcl | 73 | 14 |
| Eliquis | Apixaban | 71 | 24 |
| Trazodone Hcl | Trazodone Hcl | 69 | 15 |
| Allopurinol | Allopurinol | 68 | 18 |
| Methocarbamol | Methocarbamol | 67 | 25 |
| Levofloxacin | Levofloxacin | 63 | 44 |
| Famotidine | Famotidine | 61 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 23 |
| Mirtazapine | Mirtazapine | 57 | 13 |
| Celecoxib | Celecoxib | 55 | 16 |
| Glipizide | Glipizide | 55 | 17 |
| Xarelto | Rivaroxaban | 55 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Potassium Chloride | Potassium Chloride | 49 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 18 |
| Paxlovid | Nirmatrelvir/Ritonavir | 47 | 47 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 15 |
| Diazepam | Diazepam | 44 | 13 |
| Bupropion Xl | Bupropion Hcl | 43 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | suppressed |
| Finasteride | Finasteride | 43 | 11 |
| Glimepiride | Glimepiride | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | 13 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Cephalexin | Cephalexin | 35 | 26 |
| Temazepam | Temazepam | 35 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 24 |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 19 |
| Trulicity | Dulaglutide | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | 11 |
| Estradiol | Estradiol | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 12 |
| Valsartan | Valsartan | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $450.33 · 24 records | Novo Nordisk Inc | AREXVY, Cologuard Collection Kit, ELIQUIS, ENTRESTO, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error